Diabeteszentrum Hamburg West
- Address
- lock Available on a paid plan
Cardiovascular Diseases
At Diabeteszentrum Hamburg West, clinical research in cardiovascular diseases focuses on reducing major heart and blood vessel risks in people with atherosclerotic cardiovascular disease, heart failure, and related metabolic conditions. The trials are exploring new ways to lower LDL cholesterol and lipoprotein(a), while also evaluating whether emerging therapies can help prevent serious events such as heart attack and stroke.
- Testing new treatments to lower cardiovascular risk in people with established heart and vessel disease
- Studying therapies aimed at reducing LDL-C and lipoprotein(a) levels
- Evaluating whether investigational approaches can help prevent major adverse cardiovascular events
This area includes research on ASCVD, prevention of heart failure, and broader strategies to improve long-term cardiovascular outcomes in patients with high risk.
Nutritional and Metabolic Diseases
The site conducts extensive studies in nutritional and metabolic diseases, especially obesity, overweight, and type 2 diabetes. Much of the work is centered on helping people achieve meaningful weight loss, improve glycemic control, and manage obesity-related complications through new treatment options.
- Investigating therapies for weight loss in adults with overweight or obesity
- Evaluating treatments for type 2 diabetes mellitus and improved blood sugar control
- Studying approaches for people with obesity and related comorbidities
Research here also includes people living with type 1 diabetes, chronic weight management needs, and obesity linked to other health conditions, with the goal of improving everyday disease control and overall metabolic health.
Respiratory Tract Diseases
Research in respiratory tract diseases at this Hamburg site is strongly linked to obstructive sleep apnea, particularly in people who also have overweight or obesity. These studies are examining whether new therapies can improve sleep apnea severity while also supporting weight reduction and better overall health.
- Studying treatment options for adults with obstructive sleep apnea and excess body weight
- Assessing whether new therapies can improve the Apnea-Hypopnea Index
- Exploring combined benefits for sleep-related breathing problems and weight management
The research includes both treated and untreated sleep apnea populations, reflecting a practical effort to improve symptoms and support better long-term outcomes in people with overlapping metabolic and respiratory disease.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 5 by active trials.
- 1Eli Lilly & Co.2active
lock +4 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Amgen Inc.4trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Diabeteszentrum Hamburg West
lock Showing 1 of 16 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus. | Amgen Inc. | Phase II | Not Recruiting | Mar 2023 | Oct 2025 |
IMP list
lock Showing 1 of 15 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Maridebart Cafraglutide | 4 | Unknown | 2023-03-10 | 2026-02-17 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.